|
1
|
Vinik A, Casellini C, Perry RR, Feliberti
E and Vingan H: Diagnosis and management of pancreatic
neuroendocrine tumors (PNETS). De Groot LJ, Chrousos G and Dungan
K: Endotext, MDText.com, Inc. (South Dartmouth, MA). 2000.
|
|
2
|
Simard EP, Ward EM, Siegel R and Jemal A:
Cancers with increasing incidence trends in the United States: 1999
through 2008. CA Cancer J Clin. 62:118–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dasari A, Shen C, Halperin D, Zhao B, Zhou
S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence,
and survival outcomes in patients with neuroendocrine tumors in the
United States. JAMA Oncol. 3:1335–1342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chiruvella A and Kooby DA: Surgical
management of pancreatic neuroendocrine tumors. Surg Oncol Clin N
Am. 25:401–421. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kidd M, Modlin I and Oberg K: Towards a
new classification of gastroenteropancreatic neuroendocrine
neoplasms. Nat Rev Clin Oncol. 13:691–705. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haynes AB, Deshpande V, Ingkakul T, Vagefi
PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL and
Fernández-del Castillo C: Implications of incidentally discovered,
nonfunctioning pancreatic endocrine tumors: Short-term and
long-term patient outcomes. Ach Surg. 146:534–538. 2011.
|
|
7
|
Solorzano CC, Lee JE, Pisters PW, Vauthey
JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA and Evans DB:
Nonfunctioning islet cell carcinoma of the pancreas: Survival
results in a contemporary series of 163 patients. Surgery.
130:1078–1085. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei IH, Harmon CM, Arcerito M, Cheng DF,
Minter RM and Simeone DM: Tumor-associated macrophages are a useful
biomarker to predict recurrence after surgical resection of
nonfunctional pancreatic neuroendocrine tumors. Ann Surg.
260:1088–1094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bajorath J: Molecular organization,
structural features, and ligand binding characteristics of CD44, a
highly variable cell surface glycoprotein with multiple functions.
Proteins. 39:103–111. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thapa R and Wilson GD: The importance of
CD44 as a stem cell biomarker and therapeutic target in cancer.
Stem Cells Int. 2016:20872042016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naor D, Wallach-Dayan SB, Zahalka MA and
Sionov RV: Involvement of CD44, a molecule with a thousand faces,
in cancer dissemination. Semin Cancer Biol. 18:260–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ponta H, Sherman L and Herrlich PA: CD44:
from adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Naor D, Nedvetzki S, Golan I, Melnik L and
Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu L, Wu M, Sun L, Li W, Fu W, Zhang X and
Liu T: Clinicopathological and prognostic significance of cancer
stem cell markers CD44 and CD133 in patients with gastric cancer: A
comprehensive meta-analysis with 4729 patients involved. Medicine.
95:e51632016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang SJ and Bourguignon LY: Role of
hyaluronan-mediated CD44 signaling in head and neck squamous cell
carcinoma progression and chemoresistance. Am J Pathol.
178:956–963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang SJ, Ou-Yang F, Tu HP, Lin CH, Huang
SH, Kostoro J, Hou MF, Chai CY and Kwan AL: Decreased expression of
autophagy protein LC3 and stemness
(CD44+/CD24−/low) indicate poor prognosis in
triple-negative breast cancer. Hum Pathol. 48:48–55. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jian-Hui C, Er-Tao Z, Si-Le C, Hui W,
Kai-Ming W, Xin-Hua Z, Chaung-Qi C, Shi-Rong C and Yu-Long H: CD44,
Sonic Hedgehog, and Gli1 expression are prognostic biomarkers in
gastric cancer patients after radical resection. Gastroenterol Res
Pract. 2016:10130452016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Q, Zhou H, Liu Q, Cao Y, Wang G, Hu
A, Ruan L, Wang S, Bo Q, Chen W, et al: Prognostic value of the
expression of cancer stem cell-related markers CD133 and CD44 in
hepatocellular carcinoma: From patients to patient-derived tumor
xenograft models. Oncotarget. 7:47431–47443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Durko L, Wlodarski W, Stasikowska-Kanicka
O, Wagrowska-Danilewicz M, Danielewicz M, Hogendorf P, Strzelczyk J
and Malecka-Panas E: Expression and clinical significance of cancer
stem cell markers CD24, CD44, and CD133 in pancreatic ductal
adenocarcinoma and chronic pancreatitis. Dis Markers.
2017:32768062017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iseki Y, Shibutani M, Maeda K, Nagahara H,
Ikeya T and Hirakawa K: Significance of E-cadherin and CD44
expression in patients with unresectable metastatic colorectal
cancer. Oncol Lett. 14:1025–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chanmee T, Ontong P, Kimata K and Itano N:
Key roles of hyaluronan and its CD44 receptor in the stemness and
survival of cancer stem cells. Front Oncol. 5:1802015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bourguignon LYW, Earle C and Shiina M:
Activation of matrix hyaluronan-mediated CD44 signaling, epigenetic
regulation and chemoresistance in head and neck cancer stem cells.
Int J Mol Sci. 18:18492017. View Article : Google Scholar
|
|
23
|
Ohara Y, Oda T, Sugano M, Hashimoto S,
Enomoto T, Yamada K, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K,
et al: Histological and prognostic importance of
CD44(+)/CD24(+)/EpCAM(+) expression in clinical pancreatic cancer.
Cancer Sci. 104:1127–1134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li XP, Zhang XW, Zheng LZ and Guo WJ:
Expression of CD44 in pancreatic cancer and its significance. Int J
Clin Exp Pathol. 8:6724–6731. 2015.PubMed/NCBI
|
|
25
|
Grosse-Gehling P, Fargeas CA, Dittfeld C,
Garbe Y, Alison MR and Corbeil D Kunz-Schughart LA: CD133 as a
biomarker for putative cancer stem cells in solid tumours:
Limitations, problems and challenges. J Pathol. 229:355–378. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bauer N, Fonseca AV, Florek M, Freund D,
Jaszai J, Bornhauser M, Fergeas CA and Corbeil D: New insights into
the cell biology of hematopoietic progenitors by studying
prominin-1 (CD133). Cells Tissues Organs. 188:127–138. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bellizzi A, Sebastian S, Ceglia P,
Centonze M, Divella R, Manzillo EF, Azzariti A, Silvestris N,
Montemurro S, Caliandro C, et al: Co-expression of CD133(+)/CD44(+)
in human colon cancer and liver metastasis. J Cell Physiol.
228:408–415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mokrowiecka A, Veits L, Falkeis C, Musial
J, Kordek R, Lochowski M, Kozak J, Wierzchniewska-Lawska A, Vieth M
and Malecka-Panas E: Expression profiles of cancer stem cell
markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac
mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced
esophageal adenocarcinoma sequence. Pathol Res Pract. 213:205–209.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Wu Y, Gao W, Li F, Bo Y, Zhu M, Fu
R, Liu Q, Wen S and Wang B: Identification and characterization of
CD133+CD44+ cancer stem cells from human laryngeal squamous cell
carcinoma cell lines. J Cancer. 8:497–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han SA, Jang JH, Won KY, Lim SJ and Song
JY: Prognostic value of putative cancer stem cell markers (CD24,
CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Pathol Res Prac. 213:956–963. 2017. View Article : Google Scholar
|
|
31
|
Zhou JY, Chen M, Ma L, Wang X, Chen YG and
Liu SL: Role of CD44(high)/CD133(high) HCT-116 cells in the
tumorigenesis of colon cancer. Oncotarget. 7:7657–7666. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bahnassy AA, Fawzy M, El-Wakil M, Zekri
AR, Abdel-Sayed A and Sheta M: Aberrant expression of cancer stem
cell markers (CD44, CD90, and CD133) contributes to disease
progression and reduced survival in hepatoblastoma patients: 4-year
survival data. Transl Res. 165:396–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Putzer BM, Solanki M and Herchenroder O:
Advances in cancer stem cell targeting: How to strike the evil at
its root. Adv Drug Deliv Rev. 120:89–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leon G, MacDonagh L, Finn SP, Cuffe S and
Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting
cell surface markers and signaling pathways. Pharmacol Ther.
158:71–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gaur P, Sceusi EL, Samuel S, Xia L, Fan F,
Zhou Y, Lu J Tozzi F, Lopez-Berestein G, Vivas-Mejia P, et al:
Identification of cancer stem cells in human gastrointestinal
carcinoid and neuroendocrine tumors. Gastroenterology.
141:1728–1737. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Salaria S, Means A, Revetta F, Idrees K,
Liu E and Shi C: Expression of CD24, a stem cell marker, in
pancreatic and small intestinal neuroendocrine tumors. Am J Clin
Pathol. 144:642–648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Katsuta E, Tanaka S, Mogushi K, Shimada S,
Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, et
al: CD73 as a therapeutic target for pancreatic neuroendocrine
tumor stem cells. Int J Oncol. 48:657–669. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
American Joint Committee on Cancer, TNM
Staging System for Pancreatic Neuroendocrine Tumours, . (7th).
2010.
|
|
39
|
World Health Organization Classification
of Tumours Pathology and Genetics of Pancreas Tumours, . 2010.
|
|
40
|
Hirata A, Hatano Y, Niwa M, Hara A and
Tomita H: Heterogeneity of Colon Cancer Stem Cells. Adv Exp Med
Biol. 1139:115–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Das PK, Rakib MA, Khanam JA, Pillai S and
Islam F: Novel therapeutics against breast cancer stem cells by
targeting surface markers and signaling pathways. Curr Stem Cell
Res Ther. 14:669–682, 2×x. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zagar TM, White RR, Willett CG, Tyler DS,
Papavassiliou P, Papalezova KT, Guy CD, Broadwater G, Clough RW and
Czito BG: Resected pancreatic neuroendocrine tumors: Patterns of
failure and disease-related outcomes with or without radiotherapy.
Int J Radiat Oncol Biol Phys. 83:1126–1131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mehta S, de Reuver PR, Gill P, Andrici J,
D'Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS and Gill AJ:
Somatostatin receptor SSTR-2a expression is a stronger predictor
for survival than Ki-67 in pancreatic neuroendocrine tumors.
Medicine. 94:e12812015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Boninsegna L, Panzuto F, Partelli S,
Capelli P, Fave GD, Bettini R, Pederzoli P, Scarpa A and Falconi M:
Malignant pancreatic neuroendocrine tumour: Lymph node ratio and
Ki67 are predictors of recurrence after curative resections. Eur J
Cancer. 48:1608–1615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oh TG, Chung MJ, Park JY, Bang SM, Park
SW, Chung JB and Song SY: Prognostic factors and characteristics of
pancreatic neuroendocrine tumors: Single center experience. Yonsei
Med J. 53:944–951. 2012. View Article : Google Scholar : PubMed/NCBI
|
